Drugs / RLD2401
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06595004 Comparator | Nov 2024 → Jun 2025 | chronic pain syndrome | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLD2401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06595004 ↗ |
| Route | Oral | “Take RLD2401 twice daily for 12 weeks orally.” NCT06595004 ↗ |